About Photolitec
Photolitec is a company based in Buffalo (United States) founded in 2010. It operates as a B2B. Photolitec has raised $5 million across 5 funding rounds from investors including HHS, Ami organics and Huahai Pharmaceutical. Photolitec operates in a competitive market with competitors including ImaginAb, AC Immune, PhotoPharmics, APRINOIA and BioArctic, among others.
- Headquarter Buffalo, United States
- SectorsHealthcare
- Website photolitec.org
- Total Equity Funding$5M (USD)
in 5 rounds
- Latest Funding Round$1.36M (USD), Grant
Sep 2020
- InvestorsHHS
& 3 more
Funding Insights of Photolitec
Photolitec has successfully raised a total of $5M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $1.36 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5M
- Total Rounds 5
- Last Round Grant — $1.36M
- First Round $2M
(Jan 2011)
- Investors Count 4
All 5 funding rounds of Photolitec with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $1.36M | Grant | – | – | |
| Mar 2015 | $2M | Series A | – | – | |
| Aug 2013 | $1.65M | Grant | – | – | |
| Mar 2012 | $1M | Series A | – | – | |
| Jan 2011 | $2M | Series A | – | Huahai Pharmaceutical | – |
4 investors in total: 4 institutional.
Investors in Photolitec
Photolitec has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include HHS, Ami organics and Huahai Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Advanced API intermediates are manufactured for pharmaceutical use. | 2007 | amiorganics.com | Surat, India | |
Pharmaceutical APIs, formulations, and animal health products are manufactured. | 1956 | hisunpharm.com | Taizhou, China | |
APIs, formulations, and intermediates are manufactured, specializing in pril products. | 1989 | huahaipharm.com | Taizhou, China |
Investor details for Photolitec
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Photolitec
2 people are tracked at Photolitec (1 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Ravindra K. Pandey | Founder & CSO | Leadership |
Aimee Joy Marko | Principal Investigator | Team |
Complete people profiles for Photolitec
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Photolitec
3 dated milestones of Photolitec across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Photolitec is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Grant, of $1.4M.
Competitors of Photolitec
Photolitec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ImaginAb, AC Immune, PhotoPharmics, APRINOIA and BioArctic, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| imaginab.com | 2007 | Los Angeles, United States | $59.64M | 17 | ImaginAb is focused on developing advanced immuno-oncology imaging technologies. | |
| acimmune.com | 2003 | Lausanne, Switzerland | $119.82M | – | Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases. | |
| photopharmics.com | 2011 | American Fork, United States | $43.44M | – | Non-invasive phototherapy for Parkinson's disease is developed. | |
| aprinoia.com | 2015 | Taipei, Taiwan | $51.1M | 15 | Diagnostics and therapeutics for neurodegenerative disorders are developed. | |
| bioarctic.com | 2003 | Bromma, Sweden | – | – | Disease-modifying treatments for neurodegenerative diseases are developed. | |
| blueearthdiagnostics.com | 2014 | Oxford, United Kingdom | $49.42M | 38 | Radioactive molecular imaging agents for cancer are developed. | |
| nuviewlifesciences.com | 2005 | Park, United States | $90M | – | Cancer diagnosis devices targeting VPAC1 receptors are developed. |
Detailed competitors of Photolitec
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Photolitec
10 companies that operate in the same segment as Photolitec (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Photolitec
Photolitec was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Photolitec is headquartered in Buffalo, United States. It is registered at Buffalo, New York, United States.
Photolitec is a funded company, having raised a total of $5M across 5 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Jan 2011.
Photolitec, founded in 2010 in Buffalo, United States, focuses on providing healthcare solutions, advancing biotech innovations, medical imaging, and cancer therapy. Supplies photosensitizing compounds for tumor imaging and photodynamic cancer therapy. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Photolitec's top competitors include ImaginAb, AC Immune and PhotoPharmics.
Photolitec has 4 investors. Key investors include HHS, Ami organics, Huahai Pharmaceutical, and Zhejiang Hisun Pharmaceuticals.